Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLATOYOSI M ODENIKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1194887646
CMS profile
99079
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11,923.60

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,130.00 3
Compensation for serving as faculty or as a speaker for a medical education program $3,571.16 3
Honoraria $2,156.00 1
Food and Beverage $60.85 2
Education $5.59 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $3,635.59 2
Taiho Oncology, Inc. $2,500.00 2
Blueprint Medicines Corporation $2,216.85 3
Celgene Corporation $2,076.00 1
Servier Pharmaceuticals LLC $1,495.16 2

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLATOYOSI M ODENIKE

NPI 1194887646 · CMS profile ID 99079

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194887646?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194887646?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194887646?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1194887646?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $11,923.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Blueprint Medicines Corporation $2,156.0012/16/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848932709 CMS
Blueprint Medicines Corporation $17.3812/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848932705 CMS
Blueprint Medicines Corporation $43.4712/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848932707 CMS
Servier Pharmaceuticals LLC $755.0006/15/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852924315 CMS
Servier Pharmaceuticals LLC $740.1605/20/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852924313 CMS
Celgene Corporation $2,076.0005/13/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783675269 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,630.0003/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820118113 CMS
Taiho Oncology, Inc. $1,250.0002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383503 CMS
Taiho Oncology, Inc. $1,250.0002/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383497 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.5902/15/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820118109 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,975.41 13
PY2020 $8,990.00 3
PY2021 $11,923.60 10
PY2023 $16,954.12 16
PY2024 $3,862.50 4
PY2025 $4,631.25 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,498.65 16
PY2024 Recipient $579.84 2
PY2024 Principal investigator $57,505.53 9
PY2023 Principal investigator $540,389.47 36
PY2022 Principal investigator $455,007.19 49
PY2021 Principal investigator $651,058.16 62
PY2020 Recipient $3,300.00 1
PY2020 Principal investigator $749,494.38 87
PY2019 Principal investigator $687,194.48 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $7,131.74 12/30/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-415 No dispute reported 06/30/2026 647602787
Principal investigator 1 AbbVie, Inc. $6,187.50 12/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602627
Principal investigator 1 AbbVie, Inc. $55,062.50 12/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
A18-877 No dispute reported 06/30/2026 647602621
Principal investigator 1 AbbVie, Inc. $3,250.00 12/11/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602629
Principal investigator 1 AbbVie, Inc. $5,250.00 12/11/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602633
Principal investigator 1 AbbVie, Inc. $2,511.25 12/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602631
Principal investigator 1 AbbVie, Inc. $3,250.00 12/03/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602625
Principal investigator 1 AbbVie, Inc. $6,961.74 12/02/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602623
Principal investigator 1 AbbVie, Inc. $7,075.49 11/27/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-415 No dispute reported 06/30/2026 647602793
Principal investigator 1 AbbVie, Inc. $4,837.50 11/25/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602641
Principal investigator 1 AbbVie, Inc. $655.36 11/14/2019 Non-covered Recipient Entity
University Of Chicago
A18-877 No dispute reported 06/30/2026 708434295
Principal investigator 1 AbbVie, Inc. $1,639.04 11/14/2019 Non-covered Recipient Entity
University Of Chicago
A18-877 No dispute reported 06/30/2026 708434297
Principal investigator 1 AbbVie, Inc. $3,278.08 11/14/2019 Non-covered Recipient Entity
University Of Chicago
A18-877 No dispute reported 06/30/2026 708434299
Principal investigator 1 AbbVie, Inc. $6,556.16 11/14/2019 Non-covered Recipient Entity
University Of Chicago
A18-877 No dispute reported 06/30/2026 708434301
Principal investigator 1 AbbVie, Inc. $49,171.20 11/14/2019 Non-covered Recipient Entity
University Of Chicago
A18-877 No dispute reported 06/30/2026 708434303
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 11/07/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887073
Principal investigator 1 AbbVie, Inc. $8,569.24 11/05/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-415 No dispute reported 06/30/2026 647602795
Principal investigator 1 AbbVie, Inc. $3,462.50 11/04/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602639
Principal investigator 1 AbbVie, Inc. $4,593.75 10/30/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602613
Principal investigator 1 Incyte Corporation $2,455.00 10/24/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436365
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $5,250.00 10/24/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR CDAI E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS No dispute reported 06/30/2026 683887069
Principal investigator 1 AbbVie, Inc. $46,737.50 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602611
Principal investigator 1 Agios Pharmaceuticals, Inc. $500.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation No dispute reported 06/30/2026 701370711
Principal investigator 1 AbbVie, Inc. $75.00 10/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-415 No dispute reported 06/30/2026 647602777
Principal investigator 1 AbbVie, Inc. $2,325.00 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602779
Principal investigator 1 Incyte Corporation $1,000.00 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436363
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $27,500.00 10/10/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 STANDARD DOSE No dispute reported 06/30/2026 683887067
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $8,209.15 10/03/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR CDAI E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS No dispute reported 06/30/2026 683887065
Principal investigator 1 AbbVie, Inc. $8,468.75 10/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602615
Principal investigator 1 AbbVie, Inc. $9,131.25 09/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602595
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,000.00 09/19/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887061
Principal investigator 1 AbbVie, Inc. $500.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602597
Principal investigator 1 AbbVie, Inc. $750.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602599
Principal investigator 1 AbbVie, Inc. $500.00 08/30/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602589
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,250.00 08/14/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 andor IDH2 Mutation No dispute reported 06/30/2026 701370519
Principal investigator 1 AbbVie, Inc. $26,250.00 08/06/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602587
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,000.00 08/02/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation No dispute reported 06/30/2026 701370459
Principal investigator 1 AbbVie, Inc. $3,500.00 07/30/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602579
Principal investigator 1 AbbVie, Inc. $6,591.00 07/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-109 No dispute reported 06/30/2026 647602759
Principal investigator 1 Incyte Corporation $500.00 07/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436333
Principal investigator 1 AbbVie, Inc. $2,325.00 07/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602761
Principal investigator 1 Gilead Sciences, Inc. $2,215.00 07/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) No dispute reported 06/30/2026 676524431
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $4,235.64 07/11/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887053
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,750.00 07/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 andor IDH2 Mutation No dispute reported 06/30/2026 701370391
Principal investigator 1 AbbVie, Inc. $1,181.25 07/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602581
Principal investigator 1 Incyte Corporation $2,455.00 07/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436271
Principal investigator 1 AbbVie, Inc. $1,500.00 06/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602575
Principal investigator 1 AbbVie, Inc. $625.00 06/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602577
Principal investigator 1 AbbVie, Inc. $5,250.00 06/06/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-109 No dispute reported 06/30/2026 647602741
Principal investigator 1 AbbVie, Inc. $30,688.00 06/06/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M16-415 No dispute reported 06/30/2026 647602743
Principal investigator 1 Gilead Sciences, Inc. $4,000.00 06/03/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) No dispute reported 06/30/2026 676524425
Principal investigator 1 AbbVie, Inc. $956.25 05/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602567
Principal investigator 1 AbbVie, Inc. $4,875.00 05/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602529
Principal investigator 1 Agios Pharmaceuticals, Inc. $130.00 05/22/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation No dispute reported 06/30/2026 701370335
Principal investigator 1 Janssen Research & Development, LLC $130.00 05/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Randomized, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat (GRN163L) in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated with Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 654263113
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,250.00 05/16/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 andor IDH2 Mutation No dispute reported 06/30/2026 701370311
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $18,000.00 05/09/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887041
Principal investigator 1 AbbVie, Inc. $19,275.00 05/03/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602531
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $9,331.89 05/02/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887039
Principal investigator 1 AbbVie, Inc. $6,493.75 04/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602561
Principal investigator 1 AbbVie, Inc. $57.50 04/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602707
Principal investigator 1 Agios Pharmaceuticals, Inc. $500.00 04/17/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation No dispute reported 06/30/2026 701370163
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $2,548.14 04/11/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR CDAI E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS No dispute reported 06/30/2026 683887035
Principal investigator 1 AbbVie, Inc. $1,118.75 04/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602563
Principal investigator 1 Incyte Corporation $79.18 03/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436231
Principal investigator 1 Incyte Corporation $45.62 03/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436233
Principal investigator 1 Incyte Corporation $83.32 03/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436235
Principal investigator 1 Incyte Corporation $17.53 03/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436237
Principal investigator 1 Incyte Corporation $499.82 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436137
Principal investigator 1 Incyte Corporation $84.44 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436225
Principal investigator 1 Incyte Corporation $35.76 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436227
Principal investigator 1 Incyte Corporation $226.70 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436229
Principal investigator 1 Incyte Corporation $1,233.27 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436323
Principal investigator 1 Incyte Corporation $174.78 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436325
Principal investigator 1 Incyte Corporation $30.00 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436327
Principal investigator 1 Incyte Corporation $27.84 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436329
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $8,782.88 03/28/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887033
Principal investigator 1 AbbVie, Inc. $2,250.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602683
Principal investigator 1 AbbVie, Inc. $75.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602685
Principal investigator 1 Celgene Corporation $43,024.43 03/14/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) (AG-221-AML-005) No dispute reported 06/30/2026 675419267
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,000.00 03/14/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887027
Principal investigator 1 Incyte Corporation $500.00 03/13/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis No dispute reported 06/30/2026 708436197
Principal investigator 1 AbbVie, Inc. $1,500.00 03/12/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602549
Principal investigator 1 AbbVie, Inc. $500.00 03/12/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602551
Principal investigator 1 Janssen Research & Development, LLC $5,250.00 03/07/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 654263123
Principal investigator 1 AbbVie, Inc. $7,341.74 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602537
Principal investigator 1 AbbVie, Inc. $6,531.25 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602543
Principal investigator 1 AbbVie, Inc. $3,416.74 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602653
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,209.38 02/28/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887025
Principal investigator 1 AbbVie, Inc. $13,125.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602533
Principal investigator 1 AbbVie, Inc. $5,250.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602535
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $17,350.89 02/15/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887023
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,135.00 02/14/2019 Non-covered Recipient Entity
The University Of Chicago
Phase I Study of MEK Inhibitor Selumentinib in Combination with Azacitidine in Patients with Higher Risk Chronic Myeloid Neoplasia- MDS, MDS MPNs and Myelofibrosis No dispute reported 06/30/2026 684993463
Principal investigator 1 Janssen Research & Development, LLC $2,345.00 02/11/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Randomized, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat (GRN163L) in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated with Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 654263111
Principal investigator 1 AbbVie, Inc. $2,300.00 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602539
Principal investigator 1 AbbVie, Inc. $13,918.75 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-531 No dispute reported 06/30/2026 647602541
Principal investigator 1 Gilead Sciences, Inc. $4,000.00 01/30/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) No dispute reported 06/30/2026 676524413
Principal investigator 1 AbbVie, Inc. $3,850.00 01/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M15-522 No dispute reported 06/30/2026 647602557
Principal investigator 1 AbbVie, Inc. $62.50 01/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO HOSPITALS
M14-546 No dispute reported 06/30/2026 647602699
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $12,366.01 01/25/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS AND CHRONIC MYELOMONOCYTIC LEUKEMIA CMML No dispute reported 06/30/2026 683887021
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $4,246.90 01/17/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR CDAI E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES MDS No dispute reported 06/30/2026 683887019
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,250.00 01/11/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation No dispute reported 06/30/2026 701369963
Principal investigator 1 Celgene Corporation $13,826.88 01/11/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
PhII CC-486 mono and combo with Durvalumab in MDS Post HMA failures ) (CC-486-MDS-006) No dispute reported 06/30/2026 675419561
Principal investigator 1 Celgene Corporation $921.00 01/08/2019 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) (AG-221-AML-005) No dispute reported 06/30/2026 675419269